Page last updated: 2024-10-15

l 668169

Description

L 668169: tachykinin antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16132190
MeSH IDM0205725

Synonyms (11)

Synonym
l-668169
cyclo(gln-d-trp-n-mephe-(r)gly(anc-2)leumet)2
l-668,169
l-phenylalanine, n-(2-(3-((n-(2-(3-amino-2-oxo-1-pyrrolidinyl)-4-methyl-1-oxopentyl)-l-methionyl-l-glutaminyl-d-tryptophyl-n-methyl-l-phenylalanyl)amino)-2-oxo-1-pyrrolidinyl)-4-methyl-1-oxopentyl)-l-methionyl-l-glutaminyl-d-tryptophyl-n-methyl-, cyclic (
l 668169
137012-28-3
l 668,169
(3r-(1(s*(r*(s*))),3r*))-n-(2-(3-((n-(2-(3-amino-2-oxo-1-pyrrolidinyl)-4-methyl-1-oxopentyl)-l-methionyl-l-glutaminyl-d-tryptophyl-n-methyl-l-phenylalanyl)amino)-2-oxo-1-pyrrolidinyl)-4-methyl-1-oxopentyl)-l-methionyl-l-glutaminyl-d-tryptophyl-n-methyl-l-
3,3'-(11,30-bis((1h-indol-3-yl)methyl)-14,33-dibenzyl-2,21-diisobutyl-13,32-dimethyl-5,24-bis(2-(methylthio)ethyl)-3,6,9,12,15,22,25,28,31,34,39,40-dodecaoxo-1,4,7,10,13,16,20,23,26,29,32,35-dodecaazatricyclo[34.2.1.117,20]tetracontane-8,27-diyl)dipropana
3-[27-(3-amino-3-oxopropyl)-14,33-dibenzyl-11,30-bis(1h-indol-3-ylmethyl)-13,32-dimethyl-2,21-bis(2-methylpropyl)-5,24-bis(2-methylsulfanylethyl)-3,6,9,12,15,22,25,28,31,34,39,40-dodecaoxo-1,4,7,10,13,16,20,23,26,29,32,35-dodecazatricyclo[34.2.1.117,20]te
AKOS040745997

Dosage Studied

ExcerptReference
" All the selective NK1 receptor antagonists, tested at the concentration of 10(-5)M, induced a significant displacement to the right of the dose-response curves induced by SP and by the selective NK1 receptor agonist."( Effect of selective tachykinin receptor antagonists on the growth of human skin fibroblasts.
Maggi, CA; Morbidelli, L; Ziche, M, 1993
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]